The CASP9 Knockout HeLa Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the HeLa human cervical adenocarcinoma cell line. This product features CRISPR/Cas9-mediated gene disruption of CASP9, generating a loss-of-function model that abolishes caspase-9 expression and its downstream signaling. The polyclonal composition minimizes clonal bias, providing a robust tool for studying CASP9 deficiency.
HeLa cells are an immortalized epithelial cell line from a cervical adenocarcinoma, harboring integrated HPV18 sequences. They are characterized by rapid proliferation, robust protein expression, and well-defined signaling pathways, making them a standard host for knockout cell generation. Their broad use in cancer biology and general cell research offers a consistent genetic background for dissecting gene function. The epithelial phenotype additionally supports studies of apoptosis in carcinoma models.
Caspase-9 is the key initiator caspase of the intrinsic apoptosis pathway. Following mitochondrial cytochrome c release, it is recruited into the APAF1-containing apoptosome and activated. Active caspase-9 then cleaves and activates executioner caspases CASP3 and CASP7, which target substrates such as PARP and ICAD to drive cell death. This cascade is governed by BCL-2 family proteins (BAX, BAK, BCL-2, BCL-XL) that regulate mitochondrial permeabilization, and is modulated by XIAP inhibitor and SMAC/DIABLO activator. Caspase-9 thus serves as a central integration point for mitochondrial death signals.
In HeLa cancer cells, CASP9 knockout eliminates a critical apoptotic control point, conferring profound resistance to mitochondrial-dependent death stimuli like DNA damage or growth factor withdrawal. This mirrors apoptosis evasion in many cancers and provides a defined model for investigating intrinsic apoptosis resistance. The knockout enables evaluation of cytotoxic drug dependence on the mitochondrial pathway and validation of therapies such as BH3 mimetics that seek to reactivate apoptosis downstream of BCL-2 proteins, making it a valuable platform for preclinical cancer drug testing.
The CASP9 Knockout HeLa Polyclonal Cells support diverse experimental approaches, including Annexin V/PI apoptosis assays, caspase-3/7 activity measurements, western blotting for cleaved caspase-9 and downstream substrates, cytochrome c release analysis, and cell viability studies under chemotherapeutic agents. These cells are useful for CRISPR knockout validation, apoptotic pathway dissection, and comparative studies with wild-type HeLa cells. Typical applications include cancer drug screening, mitochondrial apoptosis research, and mechanism-of-action studies for pro-apoptotic compounds. For further details, please contact Ascent Research.
